Wealthfront’s Incyte INCY Stock Holding History

Wealthfront’s Portfolio INCY Stock Details INCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,960	Closed	-$262K	–	468
2017 Q1	$262K	Buy	+1,960	New	+$250K	﹤0.01%	362

Other funds holding INCY

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wealthfront's INCY Position: Q2 2017 in Review

Wealthfront sold out of Incyte (INCY) in Q2 2017, closing a stake of 1,960 shares — an estimated $262K sold.

Wealthfront first reported a position in INCY in Q1 2017 and held it in 1 quarter. The position peaked at $262K in Q1 2017. 493 funds tracked by Wall St. Rank hold INCY as of Q2 2017.

Wealthfront reported no remaining Incyte position as of Q2 2017 after selling out during the quarter.
Wealthfront sold 1,960 Incyte shares in Q2 2017, an estimated $262K.
Wealthfront first reported a position in Incyte in Q1 2017 and held it in 1 quarter.
Wealthfront's Incyte position peaked at $262K in Q1 2017.
493 funds tracked by Wall St. Rank held Incyte as of Q2 2017.

Based on Wealthfront's 13F filing for Q2 2017, filed 11 Aug 2017.